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Oligodendrocyte precursor cells (OPCs) have shown high promise as a transplant population to promote
regeneration in the central nervous system, specifically, for the production of myelin – the protective sheath
around nerve fibers. While clinical trials for these cells have commenced in some areas, there are currently key
barriers to the translation of neural cell therapies. These include the ability to (a) image transplant populations
in vivo; (b) genetically engineer transplant cells to augment their repair potential; and (c) safely target cells to sites
of pathology. Here, we review the evidence that magnetic nanoparticles (MNPs) are a ‘multifunctional nanoplatform’
that can aid in safely addressing these translational challenges in neural cell/OPC therapy: by facilitating real-time
and post-mortem assessment of transplant cell biodistribution, and biomolecule delivery to transplant cells, as well
as non-invasive ‘magnetic cell targeting’ to injury sites by application of high gradient fields. We identify key issues
relating to the standardization and reporting of physicochemical and biological data in the field; we consider that it
will be essential to systematically address these issues in order to fully evaluate the utility of the MNP platform for
neural cell transplantation, and to develop efficacious neurocompatible particles for translational applications.
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OPC transplantation therapies for regenerative neurology
Oligodendrocyte precursor cells (OPCs) are proliferative,
stem-like cells of the central nervous system (CNS) that
have emerged as a key transplant population to promote
repair of myelin (the protective, fatty insulating sheath
around nerve fibers) [1]. Myelin damage is a key con-
tributor to the pathology of Multiple Sclerosis and spinal
cord injury (SCI) [2-5]. The regenerative properties of
OPCs are largely due to their capacity to generate oligo-
dendrocytes, the cells that form myelin around nerve fibers
[1] (Figure 1), but some evidence suggests that these
cells may also dampen destructive processes in path-
ology sites [6].
Transplantation of OPCs derived from a range of cell
sources enhances myelin repair in animal models, in-
cluding extensive myelin genesis and rescue from lethal* Correspondence: d.chari@keele.ac.uk
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unless otherwise stated.conditions in dysmyelinating/ hypomyelinating mutant
rodents [6-9]. Introduction of human OPCs into newborn
shiverer mice resulted in extensive myelination, neuro-
logical improvement and enhanced survival in ~26% of
mice [10]. Givogri et al. transplanted primary OPCs into a
neonatal mouse model of metachromatic leukodystrophy,
a genetic disorder leading to demyelination and extensive
loss of oligodendrocytes [11]; transplant populations gen-
erated myelinating oligodendrocytes, identifiable one year
post-transplantation, with motor function significantly im-
proved compared with controls. Human embryonic stem
cell (ESC)-derived OPCs, transplanted into adult rodent
models of SCI, demonstrated remyelination and associated
improvement in motor function [12]. From a clinical per-
spective, OPC transplant populations can be derived from
numerous sources [13-16], expanded in vitro [14-16], have
a good preclinical safety record [17] and have been ap-
proved for clinical trial (Geron Corporation, California;
GRNOPC1 cells; phase I clinical trial for transplantation
of human ESC-derived OPCs into acute SCI [17-19]). This
trial recruited 5 of the 10 patients originally intended [20],Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Schematic diagram illustrating the developmental stages of the oligodendroglial lineage. Oligodendrocyte precursor cells
(OPCs) are proliferative cells which generate myelinating oligodendrocytes, as shown. The insets show typical OPCs (A2B5+) and oligodendrocytes
(MBP+) derived from primary rat cultures (cell culture and immunostaining protocols are detailed in Additional file 1).
Figure 2 Schematic diagram illustrating possible MNP features.
Iron oxides (typically magnetite, Fe3O4, or maghemite, γ-Fe2O3) pro-
vide contrast for MRI and confer ‘superparamagnetism’ to the final
particle. A protective biocompatible coating may be functionalized
to carry drugs, cell targeting molecules, fluorophores for histological
detection and/or nucleic acids for gene delivery.
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on financial grounds [18,21-23]. No adverse effects have
been reported within one year of transplantation, and a
US clinical trials database now lists this study as ‘complete’
(www.clinicaltrials.gov, trial identifier NCT01217008,
accessed 01 July 2014) [18,22]. Patients will be followed-
up at both 5 and 15 years post-transplantation [20].
Through a deal with BioTime, Asterias Biotherapeutics
have acquired the GRNOPC1 stocks (renamed AST-
OPC1) and ‘plan to seek FDA clearance to reinitiate human
clinical trials’ (asteriasbiotherapeutics.com/our-clinical-
focus/opc1/, accessed 01 July 2014) [24]. In a review of
24 preclinical OPC transplant studies for SCI models,
no instances of teratomas, systemic toxicity, allodynia,
increased mortality or allogeneic immune responses
were recorded [17].
While such progress in OPC transplantation is highly
promising, neural cell therapies still face a number of
technical issues/hurdles with respect to testing their effi-
cacy for clinical translation. Here, we review the evi-
dence that magnetic nanoparticles (MNPs) have high
utility as multifunctional tools in addressing key chal-
lenges in OPC transplantation therapies, most notably
in cell tracking. The term MNP encompasses physico-
chemically diverse synthetic particles, the common
element being a magnetic component (Figure 2). This
review will focus on particles containing the most
widely used magnetic material, iron oxides - these have
a good safety profile, with some formulations receiving
approval for clinical applications: e.g. ferucarbotran
(Resovist), Feridex (Endorem), Ferumoxsil (Lumirem/
Gastromark) and Ferumoxtran-10 (Combidex/Sinerem)
as MRI contrast agents [25]; NanoTherm for hyperther-
mic tumor therapy [26]; ferumoxytol (Feraheme) for
iron-deficiency anemia [27].Review
The MNP platform can address key challenges
confronting OPC transplantation therapies
For neural cell therapies, non-invasive tracking of trans-
planted cells is essential to correlate functional neuro-
logical recovery with transplant cell biodistribution [28].
Further, post-mortem histological analyses are required
to assess transplant cell survival, rejection, differentiation
profiles and integration, including the extent of myelin
genesis. MNPs have been shown to be broadly suitable
for both non-invasive and histological imaging, serving
as contrast agents for MRI and being readily detectable
in post-mortem tissue [29-34]. MRI offers critical
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tailed anatomical imaging of inflammation, demyelin-
ation/remyelination and assessment of lesion size [35],
in parallel with transplant cell detection [26]; (b) lack of
potentially harmful radiation (in contrast to CT and PET
scanning [28]); and (c) existence of significant infrastruc-
ture and expertise in place at clinics worldwide. MNPs
provide MRI contrast for imaging through high mag-
netic moments, which disturb local magnetic field ho-
mogeneities [36], resulting in short relaxivity times in
water protons in the immediate vicinity of the particles
and loss of signal in T2*-weighted MRI images
[35,37,38]. The contrast generated is proportional to the
magnetization of the metal, and inversely proportional
to the distance between metal and water protons, so parti-
cles designed with high iron content and/or iron near their
surface are likely to provide enhanced contrast [26,37].
Clinical MRI scanners have a resolution of ~500 μm, but
high magnetic field (up to 9 T) research scanners have
demonstrated a resolution of ~10 μm [26] (although these
are unlikely to be safe for human clinical use), with recent
refinements allowing for the identification of individual
transplant cells [39]. It should be pointed out here that
MRI cannot distinguish between intracellular and extracel-
lular MNPs, and dead/dying MNP-labeled cells can there-
fore provide false-positives [40]. In order to address this
confounding issue, studies have correlated MRI contrast
with the presence of transplanted cells by post-mortem
analyses such as immunostaining. Other methods, such as
spatial correlation of MNPs with transplant cell-associated
transgene expression or myelin production have also been
used to unambiguously identify MNP-labeled OPCs within
host tissue.
OPCs can be labeled for imaging applications with
physicochemically diverse MNPs, but there is significant
inconsistency within the literature in respect of experi-
mental methodologies, particle design/characterization,
and outcome measures – leaving doubt regarding the
particle properties required to achieve optimal cell label-
ing. For example, Bulte et al. (1999) reported that CG4
cells (an oligodendroglial cell line) did not exhibit MNP-
labeling when incubated with dextran-coated MNPs,
although the authors report that “significant” MNP-
labeling of these cells was achieved when the same particles
were conjugated with anti-transferrin-receptor antibodies
(no numerical data were reported in this study regarding
the extent of cellular labeling; Table 1) [29]. When trans-
planted into spinal cord of myelin deficient (md) rats and
normal littermates, these cells migrated up to 8.4 mm from
the injection site (over 14 d), with ex vivo MRI signal cor-
relating well with iron staining and new myelin. In con-
trast, Franklin et al. (1999) successfully labeled >60% of
CG4 cells using a dextran-coated MNP without specific
cell targeting strategies [30]. These cells were detectedex vivo seven days post-transplantation into adult rat ven-
tricles. Frank et al. (2003) investigated MNP uptake in
CG4 cells using the clinically-approved formulation Feridex
(dextran-coated iron oxide particles [41-43]) with and
without a complexed transfection agent (Lipofectamine
Plus or poly-L-lysine, PLL) [33]. Labeling with unfunctio-
nalized MNPs was reportedly “low” (not detectable using
Perls’ Prussian blue iron stain), consistent with Bulte et al.’s
(1999) study, but the cells were successfully labeled using
both transfection agents. PLL-functionalized Feridex MNPs
were also used by Lepore et al. (2006) who reported that
“large numbers of Feridex particles were taken up” by trans-
genic OPCs co-cultured with “neuronal-restricted precursor
cells”; however these co-cultures were uncharacterized and
OPC-specific labeling was not quantified [32]. Five weeks
post-transplantation into adult rat spinal cord, these cells
were detected using ex vivo MRI demonstrating migration
(up to 5 mm), with good correlation between MRI con-
trast, iron staining and transgene expression [32]. From
these studies, there is insufficient data to reach conclu-
sions regarding the potential physicochemical basis for
the different labeling results obtained with dextran
coated MNPs in OPCs, as properties such as size and
zeta potential differ substantially between the studies, or
are entirely unreported.
The Bulte group reported comparable uptake levels in
CG4 cells, OPCs and other cell types, concluding that
MNP-uptake is non-specific and independent of cell
type [31,45]. However, our group has reported substan-
tial variability in MNP-uptake dynamics between neural
cell types [52]. Concentration- and time-dependent up-
take of carboxylated polystyrene MNPs was shown for
four neural cell types (microglia, astrocytes, OPCs and
oligodendrocytes) derived from primary cultures. Up to
60% of OPCs were labeled, with heterogeneity in the ex-
tent of MNP-loading. Notably, microglia exhibited very
avid and extensive MNP uptake compared with the
other cell types, with oligodendrocytes demonstrating
the lowest levels of uptake [52].
Hohnholt et al. (2010, 2011) used MNPs with the goal
of studying iron metabolism and toxicity, rather than
labeling, in OLN-93 cells (an oligodendroglial cell line)
reporting concentration-dependent uptake of both citrate-
and dimercaptosuccinic acid (DMSA) coated MNPs (up
to 300-fold increases in average intracellular iron) [47-49].
In a subsequent study, Petters et al. (2014) functional-
ized these DMSA-coated MNPs with a fluorophore and
demonstrated uptake comparable to particles lacking
conjugated fluorophores (69 nmol Fe/mg cellular pro-
tein control; ~1700 nmol/mg without fluorophore; ~1800
nmol/mg with fluorophore; to aid comparisons with other
studies, we have re-calculated these values, as described in
Additional file 1; respectively, these values are ~1 pg Fe/
cell, ~23 pg Fe/cell and ~24 pg Fe/cell) [55]. Importantly,
Table 1 Comparative data from MNP studies involving OPCs or oligodendroglial cell lines
Ref Particle Core
(nm ± SD)
Surface Size
(nm ± SD)
Zeta
(mV ± SD)
Cell type Uptake/Labeling/Transfection
[incubation conditions]
Transplant MRI Toxicity/comments
[29] MION-46 L
(CMIR, USA)
EM: 4.6 ± 1.2;
maghemite
or magnetite
Dextran DLS: 8-20 −2.0 ± 0.4
(H2O) [44]
CG4 None [48 h; 50–
500 μg Fe/ml]
n/a n/a No data supplied
MION-46
L-OX-26
Dextran +
anti-Tfr anti
body OX-26c
Not tested Not tested “numerous intracellular
vesicles”, not quantified
[48 h; 2–50 μg Fe/ml]
Myelin
deficient
(md) rat
spinal cord,
P7.
Post-mortem
excised spinal
cord, 14 d; MRI
contrast
correlated well
with iron-staining
and new myelin
Trypan blue assay:
similar viability for
labeled/unlabeled cells
[30] SPIOa 2-7d Dextran Not tested;
<400e
Not tested CG4 >60% of cells labeled
[24 h; 2 μg Fe/ml]
Adult rat
ventricles
Labeled cells
detected, post-
mortem excised
brain, 7 d
No data supplied
[45] MD-100a EM: 7-8;
maghemite
or magnetite
crystals; multiple
per particle
Carboxylated
dendrimers
SEC: 20-30 [46] Not tested;
“highly polarized”;
carboxylation
implies negative
Primary rat
NSC-derived
OPCs (LacZ+)
“remarkable high degree
of intracellular labeling”;
within vesicles/endosomes;
relaxometry: 9.3 ± 4.3 pg
Fe/cell; Ferrozine: 8.5 ± 2.0 pg
Fe/cell [48 h; 25 μg/ml]
Long-Evans
Shaker (les)
rat
ventricles,
P0
In vivo, 6 weeks
post-
transplantation;
‘excellent’ MRI
contrast correl-
ation with LacZ
expression post-
mortem
Labeled cells viable.
No difference in
growth between
labeled/unlabeled
cells
[31] MD-100a CG4 10 pg Fe/cell (control: 1 pg);
retained at 1 week in vitro
[24–48 h; 10–25 μg Fe/ml]
n/a n/a Proliferative capacity
and viability unaffected
Primary rat
NSC-derived
OPCs (LacZ+)
10 pg Fe/cell; retained
at 1 week in vitro
[24–48 h; 10–25 μg Fe/ml]
Long-Evans
Shaker (les)
rat
ventricles,
P0
In vivo, 6 weeks
post-
transplantation;
‘excellent’ MRI
contrast correl-
ation with LacZ
expression post-
mortem
Proliferative capacity
and viability unaffected
[33] Feridex
(Berlex, USA)
5; iron oxide Dextran DLS: 50-180 −31.3 (H2O) CG4 “low” [48 h; 25 μg Fe/ml] n/a Labeled cells
detected in
gelatin
No data supplied
Feridex +
Lipofectamine
Dextran +
Lipofectamine
Plus
Not tested Not tested 14.7 ± 1.7 pg Fe/cell
(control: 1.9 ± 0.9)
[48 h; 25 μg Fe/ml]
Feridex + PLL Dextran +
PLL
Not tested Not tested 3.8 ± 1.2 pg Fe/cell
[48 h; 25 μg Fe/ml]
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Table 1 Comparative data from MNP studies involving OPCs or oligodendroglial cell lines (Continued)
[32] Feridex (Berlex,
USA) + PLL
5; iron oxide Dextran +
PLL
DLS: 50-180 −31.3 (H2O) Primary rat
GRP + NRP
(transgenic)
“large numbers of particles
were taken up”; localized
to endosomes, not nuclear;
[48 h, 25 μg Fe/ml]
Adult rat
spinal cord
Labeled cells
detected, post-
mortem excised
spinal cord, 5
weeks post-
transplantation;
5 mm migration.
MNPs correlated
well with iron-
staining and
transgene
expression.
Transplanted cells
differentiate
comparably to
unlabeled cells.
Labeled transplants
elicited greater
immune response.
[47] Fe-NPa 5-20;
maghemite
Citrate Not tested Not tested OLN-93 159 ± 34 nmol Fe/mg
protein, ~2.2 pg Fe/cellf
(control: 10 ± 2, ~0.1 pg
Fe/cellf); concentration-
dependent; in intracellular
vesicles [48 h; 300 μM]
n/a n/a No effects on viability,
morphology or
proliferation. No Fe
leaching from MNPs.
[48] D-IONPa 5-20; iron
oxide
DMSA DLS: 60 −26 ± 3 (FCS−) 4200 nmol Fe/mg protein,
~57 pg Fe/cellf (control: 7,
~0.1 pg Fe/cellf);
concentration-dependent;
retained at 24 h
[8 h; 4 mM Fe]
n/a n/a Concentration-
dependent: altered
morphology, increased
ROS, decreased GSH,
but all reversible and
viability unaltered.
[49] D-IONPa 957 nmol Fe/mg protein,
~13 pg Fe/cellf (control: 5,
~0.1 pg Fe/cellf); decreased
to ~620 nmol Fe/mg at 48 h,
~8 pg Fe/cellf; concentration-
dependent; perinuclear
accumulation [24 h;
1000 μM; 55 μg Fe/ml]
n/a n/a None evident. No ROS
increase. Increased
ferritin.
[50] Neuromag (OZ
Biosciences, France)
Not tested;
~0.5% Feb
Not tested;
proprietary
DLS: ~216 [51] Not reported;
proprietary
Primary culture-
derived OPCs
~21% of cells transfected
[oscillating magnetic
field; 24 h]
Ex vivo, onto
organotypic
neural tissue
slice
n/a None evident by
morphology or cell
counts. ‘Transplanted’
cells proliferated,
differentiated,
integrated into slice.
[52] Sphero
(Spherotech, USA)
Not tested;
Polystyrene, nile
red-stained
Carboxylated
Fe3O4/
polystyrene;
15-20% Feb
EM: 200–390
(mean 360);b
DLS: 843-961
−14.3; −23.13b ~60% of cells labeled;
heterogeneous extent,
typically ‘low’. Time- and
concentration-dependent.
[24 h; 50 μg/ml]
n/a Particles in agar
gel show
concentration-
dependent
contrast
None evident by
morphology or cell
counts. Generated
MNP-labeled
oligodendrocytes.
Intracellular MNPs
appear stable.
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Table 1 Comparative data from MNP studies involving OPCs or oligodendroglial cell lines (Continued)
[53] Fe3O4-PEI-RITC
a EM: 24.3 ± 5.7;
XRD: 25.5;
Fe3O4; ~58%
Fe [54]
1800 MW PEI;
RITC [54]
Not tested +18.6 [54] ~50% [5 μg/ml],
~60% [24 h; 20 μg/ml].
Concentration-dependent.
n/a Particles show
concentration-
dependent
contrast
None evident by
morphology or
cell counts
[55] D-IONPa EM: 4-20 DMSA DLS: 53 (H2O);
52 ± 2
(medium, FCS−)
−58 ± 4 (H2O);
−20 ± 10
(medium, FCS−)
OLN-93 Specific iron: ~1700 nmol/mg
protein, ~23 pg Fe/cellf
(~30-50% represents
extracellular MNPs; control:
69 nmol/mg, ~1 pg Fe/cellf)
[FCS−; 4 h, 1 mM]
n/a n/a Unaltered LDH activity
DLS: 109 ± 23
(medium, FCS+)
−9 ± 1
(medium, FCS+)
201 ± 63 nmol/mg protein,
~3 pg Fe/cellf [FCS+]
BP-D-IONPa EM: 4-20 DMSA +
BODIPY
DLS: 63 (H2O);
61 ± 5
(medium, FCS−)
−58 ± 18 (H2O);
−28 ± 2
(medium, FCS−)
Specific iron: ~1800 nmol/mg
protein, ~24 pg Fe/cellf
(~30-50% represents
extracellular MNPs; control:
69 nmol/mg, ~1 pg Fe/cellf);
Not lysosome-associated.
[FCS−; 4 h, 1 mM]
n/a n/a Unaltered LDH activity
DLS: 138 ± 24
(medium, FCS+)
−10 ± 1
(medium, FCS+)
171 ± 15 nmol/mg, ~2 pg
Fe/cellf [FCS+]
aIn-house synthesis; bManufacturer supplied data; cInternalizing anti-transferrin receptor monoclonal antibody; dBased on patent PCT/JP93/001092; eNot reported, but measurements of electron micrograph in article
suggest <400 nm (could be MNP aggregate); fpg Fe/cell values not reported but calculated as per Additional file 1; CG4 = oligodendroglial cell line; DIV = days in vitro; DMSA = dimercaptosuccinic acid; DLS = dynamic
light scattering; EM = electron microscopy; FCS = fetal calf serum; GFP = green fluorescent protein; GRP = glial restricted precursor; GSH = glutathione, antioxidative molecule; LacZ = gene encoding β-galactosidase;
LDH = lactate dehydrogenase; MBP = myelin basic protein, oligodendrocyte marker; NRP = neuronal restricted precursor; NSC = neural stem cell; OLN-93 = oligodendroglial cell line; OPC = oligodendrocyte precursor
cell; PEI = polyethyleneimine; PLL = poly-L-lysine; RITC = rhodamine B isothiocyanate; ROS = reactive oxygen species; SEC: size exclusion chromatography; Tfr = transferrin receptor; XRD = powder X-ray diffraction.
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functionalization, an oft-omitted step (Table 1; [29,33]):
size increased by 17%, zeta potential changed from −20 to
−28 mV. This study noted nine-fold greater levels of uptake
in the absence of serum, compared to serum-supplemented
medium, illustrating the influence of the biochemical com-
position of media on particle-cell interactions.
Many MNPs are readily detected due to their metal
content, for example by simple histochemical iron stain-
ing, which in turn correlates well with MRI observations
of MNP-labeled OPCs post-transplantation [29,32]. For
particles not amenable to metal-based detection (e.g.
due to low iron content), fluorophores can be incorpo-
rated, either internally or attached to the particle surface,
facilitating post-mortem detection by fluorescence im-
aging. For example, Kircher et al. demonstrated detec-
tion of a cyanine dye (Cy5.5)-tagged dextran-coated
MNP through fluorescence microscopy of post-mortem
tissue, although this particle was used to delineate a
brain tumor, rather than to track a transplant popula-
tion [56].
Long-term tracking of transplanted cells is highly
dependent upon label retention, but dilution of MNP-
labeling has been observed in vitro and in vivo, being at-
tributed at least in part to cell proliferation [29,40]. This
represents a particular challenge for imaging the biodis-
tribution/migration of proliferative populations such as
OPCs. Although MNP retention by OPCs has been re-
ported for 7 d in vitro and 6 weeks post-transplantation
(upper limits not determined) [31,45], no studies have
systematically quantified proliferative dilution of MNPs,
or distinguished between particle loss due to cell prolif-
eration versus cellular excretion by exocytosis. A further
concern is whether particles are retained during differ-
entiation into mature oligodendrocytes, as the primary
goal of OPC therapy is to replace lost/damaged oligo-
dendrocytes [1,5]. Therefore, the ability to image these
differentiated cells long-term in areas of regeneration is
key for myelinating therapies. Oligodendrocytes are post-
mitotic cells, therefore particle loss due to proliferative di-
lution is eliminated. Indeed in our experiments, when
pulse-labeled OPCs were subsequently differentiated and
maintained for 30 days, a significant proportion (>50%) of
oligodendrocytes displayed MNP-labeling, suggesting that
the differentiated progeny can ‘inherit’ MNPs and retain
the label for long-term imaging [53].
MNPs have promising safety profiles in OPCs
In order to develop MNPs for clinical cell therapies, it is
of paramount importance to assess their potential cyto-
toxic effects in neural transplant populations. Oligo-
dendroglial cells contain more iron than any other CNS
cell type, but are also the most vulnerable to excess iron,
which typically leads to oxidative stress due to reactiveoxygen species (ROS) [49]. It is of note that oxidative
stress has been linked with oligodendrocyte damage in
diseases such as Multiple Sclerosis [57,58], indicating
that MNP-induced genesis of ROS could be similarly
deleterious to labeled transplanted oligodendroglial cells.
In other neural cells, MNPs have been shown to impair
cellular function through mechanisms including disrup-
tion to the cytoskeleton/cell membrane [59,60] or intra-
cellular trafficking processes [61,62], and direct damage
to intracellular organelles [61] including by iron release
during particle degradation [63]. Through these or other
mechanisms, MNP uptake could also perturb cellular
behavior, including capacity for migration or prolifera-
tion [64].
The Dringen group have used the OLN-93 oligo-
dendroglial cell line to conduct the most detailed MNP-
OPC toxicity studies to date, including demonstration of
uptake of citrate-coated MNPs without affecting viability,
morphology or proliferation, and without evidence of iron
leaching [47]. Ferritin was greatly upregulated in response
to increased Fe levels, storing Fe in a redox inactive form
and protecting against iron-related toxicity [47]. A battery
of assays found no evidence of acute cytotoxicity (72 h)
for DMSA-coated MNPs [49]. For the same MNPs and
cells, another study reported morphological changes,
decreased glutathione (an antioxidative molecule) and
increased ROS, but these changes were reversible and
did not affect viability [48,65]. Consistent with these
data, OPCs labeled with other MNPs are generally re-
ported as having viability and behavior comparable to
unlabeled OPCs (Table 1; [29,31,32,45,52,53,55]).
Combinatorial therapies and OPC transplantation: using
multimodal MNPs to achieve multiple therapeutic goals
While cell therapy alone is demonstrably efficacious, a
widely-held view in the regenerative neurology commu-
nity is that ‘combinatorial’ therapies (e.g. cell transplant-
ation plus drug/gene delivery) achieve more impactful
clinical regenerative outcomes than single therapeutic
strategies [66-70]. For example, transplanting OPCs genet-
ically engineered to secrete neurotrophic factors showed
significantly greater improvement in SCI injury models
than transplanting unmodified OPCs, or fibroblasts se-
creting the same neurotrophins [68,71]. A major transla-
tional challenge currently is to achieve safe and effective
genetic engineering of transplant populations. We have
shown that MNPs can deliver both reporter and thera-
peutic genes to OPCs, a process significantly enhanced
by the use of state-of-the-art ‘magnetofection’ strategies
(applied static or oscillating magnetic fields to enhance
particle-cell contact; up to 21% transfection efficiency in
OPCs derived from primary sources) [50]. In contrast to
the precursor cells, differentiated oligodendrocytes showed
far lower transfection levels (up to 6%), suggesting that the
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make these cells relatively amenable to MNP-mediated
transfection compared with their progeny [72]. As far as we
are aware, these are the only reports of MNP-mediated gene
delivery to cells of the oligodendrocyte lineage available.
A further translational challenge is achieving targeted
delivery of transplant cells to lesions while limiting sec-
ondary pathology. Spatial manipulation of MNP-labeled
cells has been demonstrated using external magnetic
fields – a technique that could retain/localize transplant
cells at target sites by magnetic cell ‘capture’ following
intravenous/intrathecal delivery, of high relevance in sit-
uations where a limited cell source exists. For example,
an implanted magnet localized (limited dispersion of )
MNP-labeled cells at a rat spinal cord lesion site follow-
ing intrathecal delivery of mesenchymal stem cells [73]
and bone marrow stromal cells [74]. Magnetic fields
have also been used to localize MNP-labeled cells at a
specific region of the retina following intravitreal injec-
tion (reportedly ~360000 transplanted cells, compared
to ~10000 cells without applying a magnet), and follow-
ing intravenous delivery of cells (~42000 cells, compared
to ~4000 cells without applying a magnet) [75]. Magnetic
cell targeting has not yet been demonstrated for OPCs,
but may be feasible for SCI as above. Furthermore, the
superparamagnetic properties of particles used for cellTable 2 Challenges for cell transplantation therapies and the
Gene delivery to
transplant populations
Non-invasive
transplant tracking
Clinical needs • Therapeutic
biomolecule delivery
for combinatorial therapies.
• Assess on-target/
off-target delivery.
• Transgenes more
effective than separate
biomolecule delivery.
• Correlate clinical
improvement/side-eff
with cell presence.
Current methods • Viral vectors efficient but
raise clinical safety concerns
and require substantial
infrastructure.
• Plasmonic resonance
gold nanoparticles: p
but little infrastructure
particles cannot be
non-invasively manip
• Many nonviral methods
inefficient, unsafe and/or
not clinically relevant.
• Radiation exposure is
associated with CT sc
(X-rays) and PET scan
Benefits of MNPs • Comparable efficiency to
other nonviral systems.
• Provide contrast for
non-invasive MRI.
• Safe protocols developed. • Clinical MRI equipme
and expertise widelylabeling (i.e. where particle magnetic properties are exhib-
ited only in the presence of a magnetic field) can help over-
come issues of cell aggregation and blockade of capillaries
following systemic delivery [76]. In conjunction with the
imaging potential of MNP-labeled transplant populations,
the above findings highlight the high potential of MNPs to
serve as a ‘multifunctional platform’ to address key chal-
lenges in neural cell therapy [54], summarized in Table 2.
However, it should be noted that the overwhelming
majority of MNPs described so far for neural applica-
tions have been unimodal. Rapid advances in materials
chemistry in recent years have led to the development of
a spectrum of complex, multimodal MNPs which simul-
taneously mediate multiple functions [54]. For cell therap-
ies, purpose designed multimodal MNPs could mediate
cell imaging, genetic modification and magnetic cell tar-
geting. One such multimodal MNP was recently de-
scribed, with high iron content for MRI contrast (and
possibly cell targeting), a fluorophore for histological
detection, and potential for gene delivery which was
demonstrated in astrocytes – a major neural transplant
population [54]. The particles were synthesized using a
chemical grafting procedure to link polyethyleneimine
(PEI) covalently to the surface of Fe3O4 MNPs. This
methodology allowed for permanent linking of the PEI
to the MNP surface, of benefit for use in biologicalrelevant utility of magnetic nanoparticles
Cell targeting/localization Post-mortem
transplant identification
• Deliver high number
of cells to lesions.
• Assess survival,
differentiation,
integration into host.
ects
• Reduce cell loss/maximize
therapeutic effect.
• Correlate biodistribution
of cells with evidence
of regeneration.
• Minimize off-target effects.
of
romising,
; gold
ulated.
• Invasive injection into
lesion parenchyma risks
secondary damage.
• Dyes frequently leak
and label host cells.
ans
s (tracers).
• Distal intravenous/
intrathecal delivery limits
adherence/accumulation
at target.
• LacZ transgene expression
confounded by host
microglial β-galactosidase
activity.
• Cell-seeded scaffolds
require invasive delivery
at lesion site.
• Mismatched gender/
species/mutant transplants
are not clinically relevant.
• Non-invasive manipulation
of MNP-labeled cells using
magnetic fields for:
• Provide MRI contrast.
nt
available.
• Retention of cells at target
site, facilitating adhesion.
• Metals (e.g. iron)
can be stained.
• ‘Capture’ of cells from
blood/cerebrospinal fluid;
safe delivery distal to lesion.
• Fluorophores can be
incorporated into MNPs
(for preclinical testing).
Jenkins et al. Molecular and Cellular Therapies 2014, 2:23 Page 9 of 12
http://www.molcelltherapies.com/content/2/1/23fluids with high electrolyte concentrations; this also en-
abled overall particle size to be restricted to <50 nm and
resulted in high iron content for the particles (ca 65%
by weight), of potential benefit for imaging and mag-
netic targeting applications [54]. A red dye (rhodamine
B isothiocyanate, RITC) was then bound to the PEI skel-
eton, with the final particles being denoted Fe3O4-PEI-
RITC. The particles could be imaged using standard
fluorescence/confocal microscopy and MRI, and were
compatible for use with a range of histological methods
[54]. Further, the chemical design of the particles also
allowed for high versatility with respect of the use of
other functional polymers and binding chemistries for
nanoparticle functionalization, therefore particles of
greater functional complexity can be evolved from this
basic prototype. Using a simple one-step procedure, we
have found that ~60% of OPCs could be safely labeledFigure 3 OPCs can be labeled with a multimodal MNP. ~60% of OPCs
(a) Phase contrast micrograph showing Perls’ iron staining of MNPs (arrows).
MNPs, both perinuclear (crosshairs and dashed arrow) and cytoplasmic (arrow
derived from primary rat cerebral cortex cultures and plated 24 h before MNP
then fixed (4% paraformaldehyde) and immunostained [54]. Further details ca
Table 1. A2B5 is an OPC marker. RITC = rhodamine B isothiocyanate.with these novel MNPs (Figure 3, previously unpub-
lished data; particle properties can be found in Table 1,
ref [53]), highlighting the therapeutic potential of multi-
modal particles in OPC transplantation [53]. Whilst our
previous work showed that the gene delivery capacity of
the particles was low overall (<1%), we consider that
with further work directed towards enhancement of
their transfection potential, such particles can prove a
valuable ‘theragnostic’ tool for the developmental test-
ing and clinical translation of neural cell therapies for
regenerative neurology [54].
Conclusions
Biological perspectives: the need for standardization of
reporting
The MNP platform offers high promise for neural trans-
plantation applications, but the field is still in its relativederived from a primary source exhibit uptake of a multifunctional MNP.
(b) Z stack fluorescence micrograph confirming intracellular presence of
). Arrowhead indicates extracellular particle accumulation. OPCs were
incubation: Fe3O4-PEI-RITC MNPs, 20 μg/ml, 24 h [54]. Cultures were
n be found in Additional file 1. Particle characteristics are detailed in
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materials chemists and transplantation neurobiologists
are required to fully evaluate MNPs as an adjunct tool
for OPC transplantation. For example, despite the key
advantages offered by multimodal MNPs for OPC trans-
plantation, there is a critical lack of neurocompatible
and multimodal MNPs, representing a major scientific
and commercial gap. The potential for magnetic cell tar-
geting of OPCs to injury foci has never been assessed,
and the processes of proliferative dilution and particle
‘inheritance’ by daughter oligodendrocytes are poorly
understood. Further, much of the research investigating
MNP uptake and handling by OPCs has relied on cell
lines, whose behavior can differ markedly from primary
cells – consequently, biological data derived from cell
lines may have limited predictive value. For example,
Pinkernelle et al. report six-fold greater MNP-labeling
in the ‘neuron-like’ cell line PC12 than in primary neu-
rons [51]; similar comparative analyses are required for
OPCs.
The standardization of data reporting from MNP-
labeling studies is essential to guide advances in nano-
particle synthesis and design. As with many biomaterials
studies, MNPs used for OPC labeling are typically not
fully characterized, yet these details are essential to iden-
tify parameters relevant for improving biomaterial de-
sign. There has been little systematic attempt to
correlate MNP physicochemical properties with extent
of OPC labeling (Table 1), of high relevance from a cell
therapy perspective. Findings regarding the ability of
oligodendroglial cells to take up MNPs without conju-
gated targeting molecules/transfection agents are contra-
dictory (e.g. Bulte [29] and Frank [33] versus Franklin
[30], all using dextran-coated MNPs); the reasons under-
pinning these differences are difficult to address in the
absence of detailed particle characterization. Typically,
reports should include size, shape and surface charge/
functionalities of the final particle, measured within
physiologically relevant media. The evaluation of OPC
interactions with MNPs possessing a wider range of
physicochemical properties can inform the tailored devel-
opment of MNPs for specific transplantation applications.
Such investigations should ideally include ultrastructural
analyses of particle-cell interactions, along with evalua-
tions of intracellular handling and particle fate to establish
cellular processing mechanisms for different particles.
This information can guide the development of MNPs
with potential for endosomal escape, or suggest specific
uptake mechanisms to which MNPs should be preferen-
tially targeted for optimal labeling.
Other substantial knowledge gaps are apparent from
the literature. Few studies report the proportions of
OPCs exhibiting MNP-labeling, or conduct assessments
of the extent of MNP-loading and its correlation withimaging capacity. More often, researchers provide an
average iron content per cell measurement, which will
mask any heterogeneity of particle accumulation within
a cell population. This is particularly relevant to primary
populations (the most likely cell source for transplant-
ation therapies) which show considerable heterogeneity
in behavior including particle uptake [52], unlike cell
lines which behave in a relatively clonal manner [77].
Most studies report limited MNP-associated cytotoxicity
in OPCs, but generally without numerical viability/safety
data, a significant shortcoming as this information is
vital to developing biocompatible particles and safe la-
beling protocols. Microarray/proteomic analyses are es-
sential for detailed molecular analyses of MNP toxicity,
particularly the long term safety of transplant popula-
tions. This should progress in parallel with functional
assays of the regenerative capacity of transplanted MNP-
labeled OPCs (e.g. cell migration and myelin genesis). It
can be predicted that such work can facilitate the devel-
opment and application of this platform technology to
neural cell therapies, in order to promote repair mecha-
nisms following neurological pathology – currently a key
goal for regenerative medicine globally.
Additional file
Additional file 1: Supplementary methods, detailing culture and
immunostaining protocols, and calculations for converting nmol Fe
per mg cellular protein to pg Fe per cell.
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